drugset
drugset / Trial / NCT02250430

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430 ↗

Phase 1 Completed 8 enrolled Novan, Inc.
NaSingle-groupOpen-labelTreatment

Summary

In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.

Timeline

Start
2014-09
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 2 % Topical
Subject BERDAZIMER SODIUM Small molecule 4 % Topical

Indications

acne